Author

Magdalena Anna Benda

Observed names: Magdalena A. Benda, Magdalena Benda

Institutions: Landeskrankenhaus Feldkirch, Private University in the Principality of Liechtenstein

Observed institutions: Landeskrankenhaus Feldkirch, Private University in the Principality of Liechtenstein

ORCID: 0000-0003-3226-1902

Observed ORCID: 0000-0003-3226-1902

OpenAlex ID: A5004264095

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

2022 · Jonathan P Piccini, Valeria Caso, et al. · The Lancet · 349

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients

2021 · Emanuel Zitt, Tamara Davidovic, et al. · Frontiers in Immunology · 63

Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients

2021 · Magdalena Benda, Beatrix Mutschlechner, et al. · British Journal of Haematology · 55

Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID‐19 vaccine in haemato‐oncological patients with no antibody response

2021 · Patrick Reimann, Hanno Ulmer, et al. · British Journal of Haematology · 41

Attrition Rates in Multiple Myeloma Treatment under Real World Conditions—An Analysis from the Austrian Myeloma Registry (AMR)

2023 · Magdalena A. Benda, Hanno Ulmer, et al. · Cancers · 11

Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data

2024 · Patrick Reimann, Ilektra-Antonia Mavroeidi, et al. · Cancer Immunology Immunotherapy · 9

SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study

2022 · Michele Atzl, Axel Muendlein, et al. · BMJ Open · 5

Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

2024 · Patrick Reimann, Verena Petzer, et al. · Annals of Hematology · 4

Real-World Data on the Efficacy of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma and Amplification 1q

2025 · Magdalena Benda, Patrick Reimann, et al. · Cancers · 3

Real-world outcomes of patients (pts) with malignant solid tumors treated with immune checkpoint inhibitors (ICI) in relation to smoking status: The SAKK 80/19 SMOKER study.

2023 · Tämer El Saadany, Ulf Petrausch, et al. · Journal of Clinical Oncology · 1

Exploring the impact of first-line durvalumab plus chemotherapy on advanced biliary tract cancer: a systematic review and meta-analysis

2025 · Patrick Reimann, Eva-Maria Schneider, et al. · The Oncologist

Works count: 11

Citation count: 541

H-index: 6

I10-index: 5